Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 8:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 1,257 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Squamous Cell Carcinoma of the Head and Neck Cancer Clear all
Completed Phase 3 Interventional

Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer

NCT00273546
View directory record Official record
Conditions
Cancer
Interventions
XRP6976 (Docetaxel/Taxotere)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 29, 2009 · Synced Oct 19, 2026, 8:27 PM EDT
Completed No phase listed Observational

Prospective Trial of Serial CT Imaging for Evaluation of Dosimetric/Volumetric Changes During IMRT for Head/Neck Cancer

NCT02003482
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
Postop IMRT for head/neck cancer, CT for Radiation Treatment Planning
Radiation · Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 19, 2026, 8:27 PM EDT
Recruiting Phase 2 Interventional

Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC

NCT06693323
View directory record Official record
Conditions
HNSCC, Head and Neck Squamous Cell Carcinoma
Interventions
AHCC®capsules
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 79 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 19, 2026, 8:27 PM EDT
Terminated Not applicable Interventional

The Use of "Smart" Body-Weight Scales for Weight and Nutritional Monitoring in Patients With Head and Neck Cancer Undergoing Radiation Therapy

NCT05457478
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Malignant Head and Neck Neoplasm
Interventions
Medical Device Qardio® smart scale Usage and Evaluation, Questionnaire Administration
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
2
States / cities
Rockville, Maryland • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 19, 2026, 8:27 PM EDT
Not listed Phase 1 Interventional

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

NCT03098160
View directory record Official record
Conditions
Pancreatic Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Prostate Cancer
Interventions
Evofosfamide, Ipilimumab
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Oct 19, 2026, 8:27 PM EDT
Terminated Phase 1 Interventional

Study of INCA 0186 in Subjects With Advanced Solid Tumors

NCT04989387
View directory record Official record
Conditions
Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Gastrointestinal (GI) Malignancies
Interventions
INCA00186, Retifanlimab, INCB106385
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 90 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 19, 2026, 8:27 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

NCT05267626
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Interventions
AU-007, Aldesleukin, Avelumab, Nivolumab
Drug
Lead sponsor
Aulos Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 19, 2026, 8:27 PM EDT
Completed Phase 2 Interventional

Docetaxel in Treating Patients With Solid Tumors

NCT00003565
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Head and Neck Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
docetaxel
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
72
States / cities
Anniston, Alabama • La Jolla, California • San Diego, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 19, 2026, 8:27 PM EDT
Terminated Phase 3 Interventional Results available

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery

NCT00113399
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
filgrastim, cisplatin, docetaxel, fluorouracil, paclitaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
125
States / cities
Birmingham, Alabama • Mobile, Alabama • Hot Springs, Arkansas + 96 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Oct 19, 2026, 8:27 PM EDT
Terminated Phase 1 Interventional Results available

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

NCT04234113
View directory record Official record
Conditions
Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Melanoma, Merkel Cell Carcinoma, Skin Squamous Cell Carcinoma, Microsatellite Instability High, Triple Negative Breast Cancer, Mesothelioma, Thymic Cancer, Cervical Cancer, Biliary Tract Cancer, Hepatocellular Carcinoma, Ovarian Cancer, Gastric Cancer, Head and Neck Squamous Cell Carcinoma, Anal Cancer
Interventions
Nanrilkefusp alfa, Pembrolizumab
Drug
Lead sponsor
SOTIO Biotech AG
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
New Haven, Connecticut • Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 19, 2026, 8:27 PM EDT
Completed Phase 2 Interventional

Paclitaxel in Treating Patients With Advanced Head and Neck Cancer

NCT00002922
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
paclitaxel
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
23
States / cities
Palo Alto, California • Stanford, California • Miami, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 19, 2026, 8:27 PM EDT
Terminated No phase listed Observational

Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer

NCT00898742
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
DNA and tissue microarray analysis, reverse transcriptase-polymerase chain reaction, mass spectrometry
Genetic · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 2, 2013 · Synced Oct 19, 2026, 8:27 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

NCT05238883
View directory record Official record
Conditions
Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma, Testicular Germ Cell Tumor, Cervical Cancer, Mesothelioma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
HFB200301, Tislelizumab
Drug
Lead sponsor
HiFiBiO Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 19, 2026, 8:27 PM EDT
Completed Phase 2 Interventional

PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery

NCT00276523
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
PEG-interferon alfa-2b, Conventional surgery, Neoadjuvant therapy
Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Oct 19, 2026, 8:27 PM EDT
Completed Phase 2 Interventional Results available

Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer

NCT00833261
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cetuximab, cisplatin, intensity-modulated radiation therapy, Nab-Paclitaxel
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
4
States / cities
Cleveland, Ohio • Dallas, Texas • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 21, 2020 · Synced Oct 19, 2026, 8:27 PM EDT
Recruiting Early Phase 1 Interventional

Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers

NCT05553782
View directory record Official record
Conditions
Salivary Gland Cancer, Adenoid Cystic Carcinoma of the Salivary Gland, Squamous Cell Carcinoma of Head and Neck, Head and Neck Cancer
Interventions
Implantable Microdevice (IMD)
Combination Product
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 19, 2026, 8:27 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer

NCT00021424
View directory record Official record
Conditions
Head and Neck Cancer, Metastatic Cancer
Interventions
recombinant fowlpox-TRICOM vaccine
Biological
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 19, 2026, 8:27 PM EDT
Active, not recruiting No phase listed Observational

De-Escalation Protocol Of HPV Mediated Oropharyngeal Squamous Cell Carcinoma

NCT04638465
View directory record Official record
Conditions
HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Clinical Stage, Oropharynx Cancer
Interventions
Transoral robotic surgery, Cisplatin - Dose Level 1, Cisplatin - Dose Level 2, Dose Level 1, Dose Level 2
Procedure · Drug · Radiation
Lead sponsor
Nebraska Methodist Health System
Other
Eligibility
19 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 19, 2026, 8:27 PM EDT
Completed Phase 3 Interventional

Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer

NCT00003139
View directory record Official record
Conditions
Head and Neck Cancer, Oral Complications
Interventions
pilocarpine hydrochloride, Placebo
Drug · Other
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
216
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 19, 2026, 8:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

NCT03693612
View directory record Official record
Conditions
Neoplasms
Interventions
feladilimab, Tremelimumab, Docetaxel, Paclitaxel, Cetuximab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 19, 2026, 8:27 PM EDT
Completed Phase 2 Interventional Results available

Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN

NCT02124707
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions
Cetuximab, Paclitaxel, Carboplatin
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Midlothian, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 19, 2026, 8:27 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

NCT05941507
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
LCB84, Anti-PD-1 monoclonal antibody
Drug
Lead sponsor
LigaChem Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Los Angeles, California • Boston, Massachusetts • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 19, 2026, 8:27 PM EDT
Recruiting Phase 1 Interventional

Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer

NCT06819228
View directory record Official record
Conditions
HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity, SCC - Squamous Cell Carcinoma
Interventions
Panitumumab IRDye 800
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 19, 2026, 8:27 PM EDT
Recruiting Phase 2 Interventional

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

NCT06535607
View directory record Official record
Conditions
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)
Interventions
Volrustomig, Cisplatin, Carboplatin, Paclitaxel, 5-FU
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 19, 2026, 8:27 PM EDT